Annual General Meeting 2023

Date: 21 March 2023

Time: 10:00 a.m. (CET)

This is Lundbeck

We are one of the only pharmaceutical companies in the world focusing exclusively on brain diseases, and we’re set apart by our specialization.

About Us

With more than 70 years of neuroscience expertise, Lundbeck has developed and commercialized some of the world's most widely prescribed therapies for brain diseases.

Our Science

LATEST NEWS

22 February, 2023 Corporate Release
Notice of Annual General Meeting
21 February, 2023 R&D News
EHDEN not-for-profit and Lundbeck collaborate on first research programme, in Neuroscience
14 February, 2023 Corporate Release
Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

See All News

Come join us in making a difference to patients worldwide.

Job Opportunities

Explore the latest financial developments at Lundbeck.

Investors

a better life for people with brain diseases

At Lundbeck, we see patients as people and are committed to support the person behind the disease.

Patients

Partnering

The complexity of brain diseases requires a concerted effort. We are committed to develop new and better treatment options from innovations born in house or externally.

Mara Formentini on working at Lundbeck

Bringing Your Whole Self to Work and its Rewards

See All Stories

Lundbeck at a glance

100

countries where our products are sold

5,400

employees supporting our purpose

1915

year Lundbeck was founded

No Health Without Mental Health

We need every brain in the game